Laia ParÃ©

List of Publications by Year
in descending order

26 papers	1,381 citations	623188 14 h-index	525886 27 g-index
27 all docs	27 docs citations	27 times ranked	1702 citing authors

#	Article	IF	Citations
1	Gene expression profiles of breast cancer metastasis according to organ site. Molecular Oncology, 2022, 16, 69-87.	2.1	24
2	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine, 2022, 75, 103801.	2.7	47
3	De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clinical Cancer Research, 2022, 28, 4995-5003.	3.2	6
4	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Npj Breast Cancer, 2021, 7, 1.	2.3	331
5	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. Npj Breast Cancer, 2021, 7, 12.	2.3	9
6	Development and validation for research assessment of Oncotype DXÂ® Breast Recurrence Score, EndoPredictÂ® and ProsignaÂ®. Npj Breast Cancer, 2021, 7, 15.	2.3	11
7	Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. Journal of Clinical Oncology, 2021, 39, 1458-1467.	0.8	73
8	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. Npj Breast Cancer, 2021, 7, 73.	2.3	2
9	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Frontiers in Immunology, 2021, 12, 792609.	2.2	3
10	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in tripleâ€negative early breast cancer: Primary translational analysis of the WSGâ€ADAPTâ€TN trial. International Journal of Cancer, 2020, 146, 262-271.	2.3	27
11	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. Journal of the National Cancer Institute, 2020, 112, 46-54.	3.0	97
12	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 33-43.	5.1	105
13	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Cancers, 2020, 12, 1902.	1.7	29
14	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptorâ€“positive HER2-negative Breast Cancer. Clinical Cancer Research, 2020, 26, 6141-6148.	3.2	6
15	PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. Frontiers in Oncology, 2019, 9, 707.	1.3	14
16	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Research, 2019, 21, 108.	2.2	21
17	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Frontiers in Oncology, 2019, 9, 303.	1.3	8
18	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. Oncologist, 2019, 24, 893-900.	1.9	25

#	Article	IF	Citations
19	Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.. Journal of Clinical Oncology, 2019, 37, 575-575.	0.8	1
20	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. Journal of Clinical Oncology, 2018, 36, 1025-1025.	0.8	3
21	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. Journal of Clinical Oncology, 2018, 36, 507-507.	0.8	6
22	Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2018, 36, e16579-e16579.	0.8	1
23	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncology, The, 2017, 18, 545-554.	5.1	250
24	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Research, 2017, 77, 2213-2221.	0.4	168
25	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. Oncotarget, 2017, 8, 21930-21937.	0.8	17
26	Prognostic Value of Intrinsic Subtypes in Hormone Receptorâ€“Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. JAMA Oncology, 2016, 2, 1287.	3.4	96